Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Porfimer sodium - Pinnacle Biologics

Drug Profile

Porfimer sodium - Pinnacle Biologics

Alternative Names: CL 184116; Photobarr; Photofrin; Photofrin II; Photofrin PDT; Photofrin Photodynamic Therapy - Axcan Pharma

Latest Information Update: 28 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator QLT
  • Developer Adare Pharmaceuticals; Novelion Therapeutics; Pinnacle Biologics; Roswell Park Cancer Institute; University of Pennsylvania
  • Class Antineoplastics; Hematoporphyrins
  • Mechanism of Action Photosensitisers; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - High-grade oesophageal dysplasia; Cholangiocarcinoma; Mesothelioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bladder cancer; Cervical cancer; Cervical dysplasia; Gastric cancer; High-grade oesophageal dysplasia; Non-small cell lung cancer; Oesophageal cancer
  • Phase III Cholangiocarcinoma
  • Phase II Brain cancer; Mesothelioma
  • No development reported Pancreatic cancer

Most Recent Events

  • 28 Jan 2019 No recent reports of development identified for phase-I development in Pancreatic-cancer(Inoperable/Unresectable, Late-stage disease) in USA (IV)
  • 24 Jun 2018 Biomarkers information updated
  • 14 Aug 2017 Concordia Laboratories initiates enrolment in a phase I trial for Non-small cell lung cancer in USA (NCT03344861)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top